Suraksha Diagnostic IPO: Subdued Market Debut with 1% Discount

Suraksha Diagnostic IPO made its stock market debut on December 6, 2024. Despite anticipation in the grey market, the shares are listed at a slight discount on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).

Performance and Listing Details

Suraksha Diagnostic shares opened at ₹437 on the BSE, a 0.90% discount from the IPO allotment price of ₹441. On the NSE, the stock debuted at ₹438, marking a 0.68% discount. This performance fell short of grey market expectations, where the shares were trading at a premium of ₹454 before the listing.

The ₹846.25 crore Issue, open from November 29 to December 3, 2024, was priced in the range of ₹420-441 per share with a lot size of 34 shares. It saw a muted overall subscription of 1.27 times, driven by Qualified Institutional Buyers (1.74 times subscription) and Non-Institutional Investors (1.41 times), while retail investors lagged with a 0.95 times subscription. The IPO was an Offer for Sale (OFS), meaning the company itself did not gain any proceeds.

Business Overview and Market Presence

Suraksha Diagnostic operates 215 customer touchpoints across West Bengal, Bihar, Assam, and Meghalaya, offering pathology, radiology, and medical consultancy services. Leveraging advanced technology platforms like LIMS, RIS, PACS, and ERP, the company has streamlined operations to maintain its market leadership in the region.

The Issue was managed by ICICI Securities, Nuvama Wealth Management, and SBI Capital Markets, with KFin Technologies serving as the registrar. Despite its robust regional presence, the tepid market response highlights investor caution toward healthcare IPOs amid market uncertainties.

Suraksha Diagnostic Live Share Price

As of 11:26 AM, The share of Suraksha Diagnostic is currently trading at ₹422.10 and is down 3.5% from its listing price. The stock has made an intraday high and an intraday low of ₹449.00 per share and ₹422.00 per share respectively.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.